Jansen revealed results from its real-world study of its cancer drug Zytiga in combination with Prednisone, to treat men with prostate cancer.
The real-world trial provide insight into the performance and the use of a drug in real situations, such are patients who can take care for themselves.
These valuable insights were shown despite the real-world study population including those who had a poor prognosis or were difficult-to-treat patients, usually excluded from clinical trials.
The drug also performed well among the patients who had metastases to internal organs.
Dr Martin Boegemann from urology department at Muenster University in Muenster, Germany, said that the new data from real-world testings confirm clinical trials.
“These new findings add to the growing bank of real-world evidence available across Europe, which is becoming more and more important in helping us choose the best treatments to transform patient outcomes,” said Boegemann.
Prostate cancer is the most commonly diagnosed cancer in men, with over 400,000 new cases diagnosed in Europe each year. Latest prostate cancer figures show that there are currently three million men living with the disease in Europe.
Zytiga has been approved in more than 90 countries and to date, has been prescribed to more than 269,500 men worldwide.